Patients were randomised in a @:@ ratio to receive oral treatment with @ mg raltegravir twice daily plus @ mg darunavir and @ mg ritonavir once daily ( NtRTI-sparing regimen ) or tenofovir-emtricitabine in a @ mg and @ mg fixed-dose combination once daily , plus @ mg darunavir and @ mg ritonavir once daily ( standard regimen ) .